


HA-PEG Layered F-PEI Core-Shell Micelles for PDGFR β Targeted Delivery of TXNDC5 Silencing for Pulmonary Fibrosis

Lauryn Carver, Zhengjie Zhou, Tzu-Han Lee, Ru-Ting Huang, Tzu-Pin Shentu, Bohao Chen, Yun Fang, and Matthew Tirrell

Pritzker School of Molecular Engineering, The University of Chicago
Department of Medicine, The University of Chicago


Email: lcarver@uchicago.edu



Highlights


- Multifunctional core-shell design enhances stability, circulation, and targeted shRNA delivery
- F-PEI self-assembles with shRNA to form compact, fully condensed cores
- PDGFR β -targeted delivery improves uptake in fibrotic lung cells
- HA-PEG shelling retains endosomal escape and ensures high cell viability
- Therapeutic efficacy in bleomycin model with reduced fibrosis and marker expression

Multicomponent Delivery Vehicle




Disease Background


Idiopathic pulmonary fibrosis (IPF) is a fatal lung disease marked by progressive, irreversible scarring. IPF involves chronic inflammation, fibroblast activation, and excess ECM deposition. Current therapies slow progression but do not reverse disease, highlighting the need for targeted treatments.



Synthesis and Assembly of shRNA/F-PEI-HA-PEG-(PDGFR β) Core-Shell Micelle Nanostructures




Core-Shell Structure Retains Effective Endosomal Escape



Endosomal Escape


Lysosomal trafficking assessed by colocalization of YOYO-1-labeled shRNA (green) with LysoTracker (red) indicates both core and core-shell particles achieve endosomal escape and nuclear accumulation. The HA-PEG shell slightly slows escape kinetics but does not abrogate delivery efficacy.

Cell Viability & TXNDC5 Knockdown



Cytotoxicity Assay


CCK-8 viability assay in murine lung fibroblasts was performed at increasing plasmid doses (0.5, 1, 2 μ g/mL) and indicated retained viability in most groups.



Gene Downregulation


RT-qPCR Analysis of TXNDC5 mRNA reveals significant knockdown in the targeted core-shell group.

Size & Morphology Characterization of Micelle Nanostructures



Size and Morphology Characterization


DLS reveals hydrodynamic radius of ~30 nm for cores and ~50 nm after shelling; TEM confirms uniform spherical morphology; zeta potential shifts from ~+34 mV (core) to ~-0.6 mV (core-shell).



Retention Assay

Self-assembly with F-PEI enables efficient plasmid condensation. Gel electrophoresis confirms complete shRNA complexation at a 1:2 shRNA to F-PEI ratio.


In Vivo Studies Indicate Effective Reduced Fibrotic Burden & Downregulated Genetic Markers of Fibrosis



Lung Histology

Masson's Trichrome staining and relative Acta2 mRNA expression show high fibrosis in PBS and core-shell targeting control (carrying non-therapeutic plasmid) groups, indicating that the delivery vehicle alone does not alter fibrosis. TXNDC5 shRNA treatment reduces collagen deposition and Acta2 levels, confirming antifibrotic efficacy.

Efficient Uptake & Receptor-Specific Targeting *In Vitro*



Cell Uptake Characterization

Confocal microscopy shows Cy5-labeled (red) micelles in fibroblasts at 0.5 and 1 h post-treatment. Nuclei stained DAPI (blue).

Receptor Specific Targeting

Flow cytometry shows higher uptake of the targeted formulation with inhibition after pre-saturation using free anti-PDGFR β antibody.

Fibrotic Marker Suppression

Immunofluorescence for α -SMA and COL1A1 shows strong fibrotic marker expression in PBS and targeting control groups. TXNDC5 shRNA treatment reduces α -SMA and COL1A1 staining, indicating effective in vivo suppression.

References

- Li, L., et al. (2017). *ACS Nano*, 11(1), 95–111.
Lee, T., et al. (2020). *Nature Communications*, 11(1), 4254.
Beljaars, L., et al. (2003). *Biochemical Pharmacology*, 66(7), 1307–1317.
Lv, J., et al. (2014). *Journal of Materials Chemistry B*, 3(4), 642–650.

Acknowledgments

The University of Chicago
Advanced Electron Microscopy
Core Facility and Soft Matter
Characterization Core Facility

Future Perspectives

Future work will evaluate aerosolized delivery of the targeted core-shell micelles via nebulization, assessing particle stability, lung deposition, and biodistribution in healthy and fibrotic models. Additional studies will examine long-term lung function, immune response, and off-target effects to support safety and translation. The modular platform can be adapted for other RNA species, CRISPR systems, or small molecules, offering broad applicability for precision therapies.